Skip to content
Clinical Trial Events
ISPOR Europe 2026

Panel Real-World Evidence (RWE) track

Bridging China and Europe: When Is China-Generated Evidence Fit for European HTA?

Tue, Nov 10, 2026 · 10:30–11:30 AM CET Hall F1, Level 0, Austria Center Vienna

About this session

ISSUE:As China’s biopharmaceutical ecosystem matures, China-generated clinical trial and real-world evidence are increasingly used to inform global development and access strategies. The key debate is no longer whether such evidence is credible, but whether it is sufficiently relevant, transferable, and decision-ready for European HTA and payer contexts.

Speakers